Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Private Client Acquisition

20 Oct 2011 07:00

RNS Number : 5093Q
Evolution Group PLC
20 October 2011
 



 

 

 

Embargoed until 07.00, 20 October 2011

 

 

 

The Evolution Group Plc

(the "Evolution Group", the "Group", the "Company")

Private Client Acquisition

 

 

The Board of The Evolution Group Plc ("Evolution") (LSE:EVG), the listed investment bank and private client investment management group, is pleased to announce that the agreement between its wholly owned subsidiary Williams de Broë Limited and BNP Paribas Wealth Management S.A. for the acquisition of the entire issued share capital of BNP Paribas Private Investment Management Limited ("PIM"), as announced on 8 August 2011 (the "Agreement"), has now been completed. Completion follows the Financial Services Authority having granted its consent to the change of control of PIM, thereby satisfying the only condition in the Agreement. 

 

The name of PIM has been changed to Williams de Broë Private Investment Management Limited.

 

 

Enquiries:

 

The Evolution Group Plc Tel: 020 7071 4300

Alex Snow, CEO Evolution Group

Philip Howell, CEO Williams de Broë Ltd

 

Pelham Bell Pottinger Tel: 020 7861 3925

Victoria Geoghegan

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURDKLFFFBFLFBZ
Date   Source Headline
17th Jun 20207:00 amRNSSFX-01 to be evaluated in COVID-19 trial
15th Jun 20205:05 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSFinal Results
8th Jun 20207:00 amRNSPaper on SFX-01 in ER positive breast cancer
5th Jun 20207:00 amRNSNotice of Results
15th May 202012:30 pmRNSStatement Re: Share Price Movement
30th Apr 20207:00 amRNSDirectorate Change
20th Feb 20209:27 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSUniversity of Rochester Collaboration
6th Feb 20207:00 amRNSUniversity of Manchester collaboration discovery
29th Jan 20202:05 pmRNSSecond Price Monitoring Extn
29th Jan 20202:00 pmRNSPrice Monitoring Extension
20th Jan 20203:39 pmRNSHolding(s) in Company
17th Jan 20203:32 pmRNSHolding(s) in Company
8th Jan 20209:52 amRNSHolding(s) in Company
17th Dec 20197:01 amRNSInvestor presentation
17th Dec 20197:00 amRNSHalf-year Report
5th Dec 20197:00 amRNSMOU with The University of Dundee
4th Dec 20193:11 pmRNSNotice of Results
14th Nov 201911:59 amRNSHolding(s) in Company
11th Nov 201912:11 pmRNSSAS study clarification
11th Nov 20197:00 amRNSSFX-01 results in SAS study
30th Sep 20197:00 amRNSESMO presentation of Phase II STEM clinical data
23rd Sep 20197:00 amRNSUpdate on extended-use phase of STEM trial
5th Sep 20197:00 amRNSAgreement for supply of SFX-01 for autism trial
28th Aug 20197:00 amRNSUpdate on SAS study
7th Aug 20197:00 amRNSGrant of further European patent
5th Aug 20197:00 amRNSResearch collaboration
25th Jul 20191:00 pmRNSGrant of Options
18th Jul 20193:47 pmRNSResult of AGM
18th Jul 20197:00 amRNSAGM Statement
24th Jun 20197:00 amRNSSFX-01 featured in SAH review paper
19th Jun 201910:39 amRNSPosting of Annual Report and AGM Notice
13th Jun 20197:00 amRNSFull Year Results
11th Jun 20197:00 amRNSNotification of Preliminary Results
22nd May 20191:32 pmRNSHolding(s) in Company
21st May 20197:00 amRNSShare Option Exercise and Issue of Equity
9th May 20195:49 pmRNSHolding(s) in Company
9th May 201910:11 amRNSHolding(s) in Company
8th May 201911:29 amRNSResult of GM and Completion of Placing
26th Apr 201911:05 amRNSSecond Price Monitoring Extn
26th Apr 201911:00 amRNSPrice Monitoring Extension
24th Apr 201911:37 amRNSHolding(s) in Company
24th Apr 201911:33 amRNSHolding(s) in Company
23rd Apr 20192:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20192:00 pmRNSPrice Monitoring Extension
23rd Apr 201910:30 amRNSHolding(s) in Company
18th Apr 20195:30 pmRNSPosting of Circular and Timing of General Meeting
17th Apr 20191:00 pmRNSPlacing and Notice of General Meeting
2nd Apr 20199:00 amRNSfinnCap publishes initiation research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.